Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs
ASCO Education - Podcast tekijän mukaan American Society of Clinical Oncology (ASCO)
Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
